Overview

Fruquintinib Renal Impairment Study

Status:
Not yet recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

A multicenter, open label, single-dose, single-period, sequential study to assess the effect of renal impairment on the pharmacokinetics of Fruquintinib

Phase:

Phase 1

Details

Lead Sponsor:

Hutchison Medipharma Limited